CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today six-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran (ALN-TTR02), an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP). These data are being presented at the American Neurological Association’s 2014 Annual Meeting being held October 12 – 14 in Baltimore.
Help employers find you! Check out all the jobs and post your resume.
